"Serotonin Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.
| Descriptor ID |
D012702
|
| MeSH Number(s) |
D27.505.519.625.850.850 D27.505.696.577.850.850
|
| Concept/Terms |
Serotonin Antagonists- Serotonin Antagonists
- 5-Hydroxytryptamine Antagonists
- 5 Hydroxytryptamine Antagonists
- Antagonists, 5-HT
- Antagonists, 5 HT
- Serotonin Receptor Blockers
- Blockers, Serotonin Receptor
- Receptor Blockers, Serotonin
- Antagonists, Serotonin
- Antiserotonergic Agents
- Agents, Antiserotonergic
- Serotonin Blockaders
- Blockaders, Serotonin
- Serotonin Receptor Antagonists
- Antagonists, Serotonin Receptor
- Receptor Antagonists, Serotonin
- 5-HT Antagonists
- 5 HT Antagonists
- Antagonists, 5-Hydroxytryptamine
- Antagonists, 5 Hydroxytryptamine
|
Below are MeSH descriptors whose meaning is more general than "Serotonin Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin Antagonists".
This graph shows the total number of publications written about "Serotonin Antagonists" by people in this website by year, and whether "Serotonin Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 0 | 2 |
| 2007 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serotonin Antagonists" by people in Profiles.
-
Zhou D, Stack GP, Lo J, Failli AA, Evrard DA, Harrison BL, Hatzenbuhler NT, Tran M, Croce S, Yi S, Golembieski J, Hornby GA, Lai M, Lin Q, Schechter LE, Smith DL, Shilling AD, Huselton C, Mitchell P, Beyer CE, Andree TH. Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists. J Med Chem. 2009 Aug 13; 52(15):4955-9.
-
Beyer CE, Cremers TI. Do selective serotonin reuptake inhibitors acutely increase frontal cortex levels of serotonin? Eur J Pharmacol. 2008 Feb 12; 580(3):350-4.
-
Zhang MY, Hughes ZA, Kerns EH, Lin Q, Beyer CE. Development of a liquid chromatography/tandem mass spectrometry method for the quantitation of acetylcholine and related neurotransmitters in brain microdialysis samples. J Pharm Biomed Anal. 2007 Jun 28; 44(2):586-93.
-
Li SX, Pequignot E, Panebianco D, Lupinacci P, Majumdar A, Rosen L, Ahmed T, Royalty JE, Rushmore TH, Murphy MG, Petty KJ. Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers. J Clin Pharmacol. 2006 Jul; 46(7):792-801.
-
Tepper SJ, Cady R, Dodick D, Freitag FG, Hutchinson SL, Twomey C, Kuhn TA. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study. Headache. 2006 Jan; 46(1):115-24.
-
Walker EA, Kohut SJ, Hass RW, Brown EK, Prabandham A, Lefever T. Selective and nonselective serotonin antagonists block the aversive stimulus properties of MK212 and m-chlorophenylpiperazine (mCPP) in mice. Neuropharmacology. 2005 Dec; 49(8):1210-9.
-
Newberg AB, Amsterdam JD, Wintering N, Ploessl K, Swanson RL, Shults J, Alavi A. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med. 2005 Jun; 46(6):973-7.
-
Rosenberg JH, Silberstein SD. The headache of SAH responds to sumatriptan. Headache. 2005 May; 45(5):597-8.
-
Beyer CE, Ghavami A, Lin Q, Sung A, Rhodes KJ, Dawson LA, Schechter LE, Young KH. Regulators of G-protein signaling 4: modulation of 5-HT1A-mediated neurotransmitter release in vivo. Brain Res. 2004 Oct 1; 1022(1-2):214-20.
-
Dodick DW, Lipsy RJ. Advances in migraine management: implications for managed care organizations. Manag Care. 2004 May; 13(5):45-51.